Cover Image
市場調查報告書

鱗狀細胞癌:開發中產品分析

Squamous Cell Carcinoma - Pipeline Review, H2 2014

出版商 Global Markets Direct 商品編碼 213051
出版日期 內容資訊 英文 145 Pages
訂單完成後即時交付
價格
Back to Top
鱗狀細胞癌:開發中產品分析 Squamous Cell Carcinoma - Pipeline Review, H2 2014
出版日期: 2014年10月31日 內容資訊: 英文 145 Pages
簡介

本報告提供鱗狀細胞癌治療藥的開發情形調查分析,提供開發中的產品概要,臨床實驗各階段的產品概要,再加上主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

簡介

  • 調查範圍

鱗狀細胞癌概要

治療藥的開發

  • 開發中的產品概要
  • 開發中產品比較分析

鱗狀細胞癌:企業開發中的治療藥

鱗狀細胞癌:大學/機關研究中的治療藥

鱗狀細胞癌:開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品

鱗狀細胞癌:企業開發中的產品

鱗狀細胞癌:大學/機關研究中的產品

鱗狀細胞癌的治療藥開發企業

  • Boehringer Ingelheim GmbH
  • Novartis AG
  • Genmab A/S
  • Celgene Corporation
  • Clinuvel Pharmaceuticals Limited
  • Oncolytics Biotech Inc.
  • Oryzon Genomics S.A.
  • Hutchison MediPharma Limited
  • Merrimack Pharmaceuticals, Inc.
  • Neotropix, Inc.
  • Axelar AB
  • Onconova Therapeutics, Inc.
  • Omeros Corporation
  • Cellceutix Corporation
  • Cannabis Science, Inc.
  • Oncovir, Inc.
  • Genextra S.p.a.
  • Bexion Pharmaceuticals, LLC.
  • AbbVie Inc.

鱗狀細胞癌:治療藥的評估

  • 單劑產品
  • 組合產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各類型分子

藥物簡介

  • afatinib
  • paclitaxel albumin-bound
  • AXL-1717
  • pelareorep
  • rigosertib sodium
  • afamelanotide
  • boanmycin hydrochloride + docetaxel
  • CIGB-128
  • DAC-0060
  • Poly-ICLC
  • BYL-719
  • LJM-716
  • interleukin-15
  • Kevetrin
  • CUV-9900
  • BXQ-350
  • CS-TATI-1
  • CS-S/BCC-1
  • TF-011-Monomethyl Auristatin E
  • AMXT-1501 + eflornithine
  • Allogenic Mesenchymal Stem Cells
  • HMPL-453
  • NTX-500
  • GPR87 Antagonist
  • GPR39 Antagonist
  • 單株抗體等

鱗狀細胞癌:最近的開發平台趨勢

鱗狀細胞癌:暫停中的計劃

鱗狀細胞癌:開發中止的產品

鱗狀細胞癌:產品開發的里程碑

  • 主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC5567IDB

Summary

Global Markets Direct's, 'Squamous Cell Carcinoma - Pipeline Review, H2 2014', provides an overview of the Squamous Cell Carcinoma's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Squamous Cell Carcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Squamous Cell Carcinoma and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Squamous Cell Carcinoma
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Squamous Cell Carcinoma and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Squamous Cell Carcinoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Squamous Cell Carcinoma pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Squamous Cell Carcinoma
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Squamous Cell Carcinoma pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Squamous Cell Carcinoma Overview
  • Therapeutics Development
    • Pipeline Products for Squamous Cell Carcinoma - Overview
    • Pipeline Products for Squamous Cell Carcinoma - Comparative Analysis
  • Squamous Cell Carcinoma - Therapeutics under Development by Companies
  • Squamous Cell Carcinoma - Therapeutics under Investigation by Universities/Institutes
  • Squamous Cell Carcinoma - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Squamous Cell Carcinoma - Products under Development by Companies
  • Squamous Cell Carcinoma - Products under Investigation by Universities/Institutes
  • Squamous Cell Carcinoma - Companies Involved in Therapeutics Development
    • AbbVie Inc.
    • Axelar AB
    • Bexion Pharmaceuticals, LLC.
    • Boehringer Ingelheim GmbH
    • Celgene Corporation
    • Clinuvel Pharmaceuticals Limited
    • Eli Lilly and Company
    • G&E Herbal Biotechnology Co., Ltd.
    • Genextra S.p.a.
    • Genmab A/S
    • Hutchison MediPharma Limited
    • InMed Pharmaceuticals Inc.
    • Karyopharm Therapeutics, Inc.
    • Neotropix, Inc.
    • Omeros Corporation
    • Oncolytics Biotech Inc.
    • Onconova Therapeutics, Inc.
    • Oncovir, Inc.
    • Otsuka Holdings Co., Ltd.
    • Pfizer Inc.
    • Sanofi
  • Squamous Cell Carcinoma - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • afamelanotide - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • afatinib - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AMXT-1501 + eflornithine hydrochloride - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Antibody Drug Conjugate to Inhibit EFGR for Squamous Cell Tumor and Glioblastoma - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AXL-1717 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • boanmycin hydrochloride - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • BXQ-350 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CIGB-128 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CS-S/BCC-1 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CS-TATI-1 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CUV-9900 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • DAC-0060 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • dacomitinib - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • HMPL-453 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • LY-2606368 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • NTX-500 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • OPB-111001 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • paclitaxel albumin bound - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • pelareorep - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Poly-ICLC - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • rigosertib sodium - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SAR-408701 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • selinexor - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Antagonize GPR39 for Esophageal Squamous Cell Carcinoma and Obesity-Related Type-2 Diabetes - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Antagonize GPR87 for Cancer - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules for Cancer - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Inhibit PLK1 for Cutaneous Squamous Cell Carcinoma - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SRT-100 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • TF-011 Monomethyl Auristatin E - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Squamous Cell Carcinoma - Recent Pipeline Updates
  • Squamous Cell Carcinoma - Dormant Projects
  • Squamous Cell Carcinoma - Discontinued Products
  • Squamous Cell Carcinoma - Product Development Milestones
    • Featured News & Press Releases
      • Sep 27, 2014: Head-to-head Phase III trial demonstrates superior progression-free survival for afatinib compared to erlotinib in patients with advanced squamous cell carcinoma of the lung
      • Mar 28, 2013: Oncolytics Biotech Meets Primary Overall Statistical Endpoint In US Phase II Study Of Reolysin In Squamous Cell Lung Cancer
      • Feb 08, 2013: Oncolytics Biotech Announces Additional Positive Reolysin Clinical Trial Data From Phase II Study In Squamous Cell Carcinoma Of Lung
      • Sep 24, 2012: Cannabis Science Initiates Preclinical Investigation Of CS-TATI-1 For European Studies For Squamous/Basal Cell Carcinomas And Kaposi's Sarcoma
      • Mar 30, 2010: Oncolytics Announces Start Of Enrollment In US Phase II SCC Lung Cancer Trial
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Squamous Cell Carcinoma, H2 2014
  • Number of Products under Development for Squamous Cell Carcinoma - Comparative Analysis, H2 2014
  • Number of Products under Development by Companies, H2 2014
  • Number of Products under Development by Companies, H2 2014 (Contd..1)
  • Number of Products under Investigation by Universities/Institutes, H2 2014
  • Comparative Analysis by Late Stage Development, H2 2014
  • Comparative Analysis by Clinical Stage Development, H2 2014
  • Comparative Analysis by Early Stage Development, H2 2014
  • Products under Development by Companies, H2 2014
  • Products under Development by Companies, H2 2014 (Contd..1)
  • Products under Investigation by Universities/Institutes, H2 2014
  • Squamous Cell Carcinoma - Pipeline by AbbVie Inc., H2 2014
  • Squamous Cell Carcinoma - Pipeline by Axelar AB, H2 2014
  • Squamous Cell Carcinoma - Pipeline by Bexion Pharmaceuticals, LLC., H2 2014
  • Squamous Cell Carcinoma - Pipeline by Boehringer Ingelheim GmbH, H2 2014
  • Squamous Cell Carcinoma - Pipeline by Celgene Corporation, H2 2014
  • Squamous Cell Carcinoma - Pipeline by Clinuvel Pharmaceuticals Limited, H2 2014
  • Squamous Cell Carcinoma - Pipeline by Eli Lilly and Company, H2 2014
  • Squamous Cell Carcinoma - Pipeline by G&E Herbal Biotechnology Co., Ltd., H2 2014
  • Squamous Cell Carcinoma - Pipeline by Genextra S.p.a., H2 2014
  • Squamous Cell Carcinoma - Pipeline by Genmab A/S, H2 2014
  • Squamous Cell Carcinoma - Pipeline by Hutchison MediPharma Limited, H2 2014
  • Squamous Cell Carcinoma - Pipeline by InMed Pharmaceuticals Inc., H2 2014
  • Squamous Cell Carcinoma - Pipeline by Karyopharm Therapeutics, Inc., H2 2014
  • Squamous Cell Carcinoma - Pipeline by Neotropix, Inc., H2 2014
  • Squamous Cell Carcinoma - Pipeline by Omeros Corporation, H2 2014
  • Squamous Cell Carcinoma - Pipeline by Oncolytics Biotech Inc., H2 2014
  • Squamous Cell Carcinoma - Pipeline by Onconova Therapeutics, Inc., H2 2014
  • Squamous Cell Carcinoma - Pipeline by Oncovir, Inc., H2 2014
  • Squamous Cell Carcinoma - Pipeline by Otsuka Holdings Co., Ltd., H2 2014
  • Squamous Cell Carcinoma - Pipeline by Pfizer Inc., H2 2014
  • Squamous Cell Carcinoma - Pipeline by Sanofi, H2 2014
  • Assessment by Monotherapy Products, H2 2014
  • Assessment by Combination Products, H2 2014
  • Number of Products by Stage and Target, H2 2014
  • Number of Products by Stage and Mechanism of Action, H2 2014
  • Number of Products by Stage and Route of Administration, H2 2014
  • Number of Products by Stage and Molecule Type, H2 2014
  • Squamous Cell Carcinoma Therapeutics - Recent Pipeline Updates, H2 2014
  • Squamous Cell Carcinoma - Dormant Projects, H2 2014
  • Squamous Cell Carcinoma - Discontinued Products, H2 2014

List of Figures

  • Number of Products under Development for Squamous Cell Carcinoma, H2 2014
  • Number of Products under Development for Squamous Cell Carcinoma - Comparative Analysis, H2 2014
  • Number of Products under Development by Companies, H2 2014
  • Number of Products under Investigation by Universities/Institutes, H2 2014
  • Comparative Analysis by Late Stage Development, H2 2014
  • Comparative Analysis by Clinical Stage Development, H2 2014
  • Comparative Analysis by Early Stage Products, H2 2014
  • Assessment by Monotherapy Products, H2 2014
  • Number of Products by Top 10 Targets, H2 2014
  • Number of Products by Stage and Top 10 Targets, H2 2014
  • Number of Products by Top 10 Mechanism of Actions, H2 2014
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2014
  • Number of Products by Top 10 Routes of Administration, H2 2014
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2014
  • Number of Products by Top 10 Molecule Types, H2 2014
  • Number of Products by Stage and Top 10 Molecule Types, H2 2014
Back to Top